BACKGROUND: The diagnosis of inflammatory bowel disease (IBD), particularly the differentiation between ulcerative colitis (UC) and Crohn's disease (CD), is difficult and delayed in many cases, despite invasive diagnostic tools. AIMS: To determine the presence and evaluate the diagnostic accuracy of the potential serological diagnostic markers perinuclear antineutrophil cytoplasmic antibodies (pANCA), autoantibodies to intestinal goblet cells (GAB) and autoantibodies to exocrine pancreas (PAB), together with combinations of these, in the diagnosis of IBD and differential diagnosis of UC and CD. METHODS: The presence of pANCA, GAB and PAB was determined in indirect immunofluorescence assay of serum samples from 71 patients with IBD (CD 43, UC 28) and 41 healthy controls. The antigen specificity of ANCA was determined using ELISA. RESULTS: Compared with the control group, we confirmed a statistically significant presence of pANCA (71.4%) and GAB (46.4%) in patients with UC and the presence of PAB only in patients with CD (30.2%) (P < 0.001). In healthy controls, neither PAB nor GAB was detected and pANCA was present in only 4.8%. The sensitivity, specificity and positive and negative predictive values in differentiation of IBD from healthy controls were as follows: pANCA(+): 71%, 95%, 91%, 83%; GAB(+): 46%, 100%, 100%, 73%; PAB(+): 30%, 100%, 100%, 58%; combination of (pANCA(+) or GAB(+))/PAB(-): 82%, 95%, 92%, 87%; and to distinguish UC from CD: pANCA(+): 71%, 98%, 95%, 84%; GAB(+): 46%, 98%, 93%, 74%; PAB(+): 30%, 100%, 100%, 48%; (pANCA(+) or GAB(+))/PAB(-): 82%, 98%, 96%, 89%. CONCLUSIONS: All three autoantibodies may be helpful tools in non-invasive diagnosis and differential diagnosis of UC and CD. Combination of the autoantibodies may be particularly helpful, as the diagnostic sensitivity is considerably improved.
BACKGROUND: The diagnosis of inflammatory bowel disease (IBD), particularly the differentiation between ulcerative colitis (UC) and Crohn's disease (CD), is difficult and delayed in many cases, despite invasive diagnostic tools. AIMS: To determine the presence and evaluate the diagnostic accuracy of the potential serological diagnostic markers perinuclear antineutrophil cytoplasmic antibodies (pANCA), autoantibodies to intestinal goblet cells (GAB) and autoantibodies to exocrine pancreas (PAB), together with combinations of these, in the diagnosis of IBD and differential diagnosis of UC and CD. METHODS: The presence of pANCA, GAB and PAB was determined in indirect immunofluorescence assay of serum samples from 71 patients with IBD (CD 43, UC 28) and 41 healthy controls. The antigen specificity of ANCA was determined using ELISA. RESULTS: Compared with the control group, we confirmed a statistically significant presence of pANCA (71.4%) and GAB (46.4%) in patients with UC and the presence of PAB only in patients with CD (30.2%) (P < 0.001). In healthy controls, neither PAB nor GAB was detected and pANCA was present in only 4.8%. The sensitivity, specificity and positive and negative predictive values in differentiation of IBD from healthy controls were as follows: pANCA(+): 71%, 95%, 91%, 83%; GAB(+): 46%, 100%, 100%, 73%; PAB(+): 30%, 100%, 100%, 58%; combination of (pANCA(+) or GAB(+))/PAB(-): 82%, 95%, 92%, 87%; and to distinguish UC from CD: pANCA(+): 71%, 98%, 95%, 84%; GAB(+): 46%, 98%, 93%, 74%; PAB(+): 30%, 100%, 100%, 48%; (pANCA(+) or GAB(+))/PAB(-): 82%, 98%, 96%, 89%. CONCLUSIONS: All three autoantibodies may be helpful tools in non-invasive diagnosis and differential diagnosis of UC and CD. Combination of the autoantibodies may be particularly helpful, as the diagnostic sensitivity is considerably improved.
Authors: H Takaishi; S Ohara; K Hotta; T Yajima; T Kanai; N Inoue; Y Iwao; M Watanabe; H Ishii; T Hibi Journal: J Gastroenterol Date: 2000 Impact factor: 7.527
Authors: T Hibi; M Ohara; K Kobayashi; W R Brown; K Toda; H Takaishi; Y Hosoda; A Hayashi; Y Iwao; M Watanabe Journal: Gut Date: 1994-02 Impact factor: 23.059
Authors: Bárbara M Schultz; Carolina A Paduro; Geraldyne A Salazar; Francisco J Salazar-Echegarai; Valentina P Sebastián; Claudia A Riedel; Alexis M Kalergis; Manuel Alvarez-Lobos; Susan M Bueno Journal: Front Immunol Date: 2017-02-28 Impact factor: 7.561
Authors: Michael P Horn; Anna Maria Peter; Franziska Righini Grunder; Alexander B Leichtle; Johannes Spalinger; Susanne Schibli; Christiane Sokollik Journal: PLoS One Date: 2018-12-17 Impact factor: 3.240